UK markets open in 4 hours 34 minutes

Auris Medical Holding AG (EARS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.6100+0.2900 (+8.73%)
At close: 4:00PM EDT
3.5500 -0.06 (-1.66%)
After hours: 07:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.3200
Bid3.5200 x 2900
Ask3.5300 x 1200
Day's range3.4500 - 4.1300
52-week range0.7260 - 6.6000
Avg. volume3,691,596
Market cap46.459M
Beta (5Y monthly)1.37
PE ratio (TTM)N/A
EPS (TTM)-1.4860
Earnings date31 Mar 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine Model of Adult T-Cell Leukemia / Lymphoma

    Treatment with OligoPhoreTM siRNA stops aggressive ATLL tumor growth to near zeroSignificant reduction in tumor size, spleen size and peripheral blood lymphocyte countsResults add to extensive body of evidence for effective OligoPhoreTM enabled delivery of nucleic acids to extrahepatic tissues Hamilton, Bermuda, June 21, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inn

  • Globe Newswire

    Auris Medical Announces Acquisition of RNA Therapeutics Company and Plans for Strategic Repositioning

    Entering field of RNA therapeutics through acquisition of Trasir Therapeutics, Inc.Trasir’s innovative peptide-based OligoPhoreTM platform designed to enable extrahepatic delivery of oligonucleotidesTrasir’s founder, Dr. Samuel Wickline, joining leadership team as Chief Scientific OfficerStrategic repositioning around RNA therapeutics and plans for spin-off or divestiture of existing programs in medium termExtraordinary general meeting of shareholders to vote on change of Company’s name to Altam

  • Globe Newswire

    Auris Medical Starts Preparations for Covid-19 Trial with Bentrio in India

    Hamilton, Bermuda, June 1, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergology, today announced that its affiliate Altamira Medica Ltd. has started preparations for the conduct of a study with its BentrioTM nasal spray for protection against airborne viruses and allergens in India. The study will seek to evaluate the efficacy of BentrioTM in the prevention and treatment of acute Covid-19 and shall start recruitment in the third quarter 2021 subject to regulatory and ethics committee approval. “In our studies in human nasal epithelium cells, Bentrio has shown to be highly effective both in protecting against SARS-CoV-2 when applied before infection onset and in reducing infectiousness when applied afterwards”, commented Thomas Meyer, Auris Medical’s founder, Chairman and CEO. “We now look forward to testing and confirming Bentrio’s efficacy also clinically. Despite great progress with vaccination programs, Covid-19 remains a major health risk and concern for many people and many countries worldwide, as evidenced by recent surges in infection rates and the continued emergence of virus variants.” About BentrioTM BentrioTM (AM-301) is a drug-free nasal spray for personal protection against airborne viruses and allergens. Upon application into the nose, BentrioTM forms a protective gel layer on the nasal mucosa. This thin film is designed to prevent the contact of viruses or allergens with cells; in addition, the composition serves to bind such particles and help with their discharge and to humidify the nasal mucosa. Together, this is designed to reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms. About Auris Medical Auris Medical is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase 1b). Through its affiliate Altamira Medica, the Company is developing a nasal spray for protection against airborne viruses and allergens BentrioTM (AM-301). In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol “EARS.” Forward-looking Statements This press release may contain statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Auris Medical’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may”, “might”, “will”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “projects”, “potential”, “outlook” or “continue”, or the negative of these terms or other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the approval and timing of commercialization of AM-301, Auris Medical’s need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Auris Medical’s product candidates, the clinical utility of Auris Medical’s product candidates, the timing or likelihood of regulatory filings and approvals, Auris Medical’s intellectual property position and Auris Medical’s financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical’s capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption “Risk Factors” in Auris Medical’s Annual Report on Form 20-F for the year ended December 31, 2020, and in Auris Medical's other filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Auris Medical or to persons acting on behalf of Auris Medical are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. Investor contact: